Image Source : Medical Dialogues
Dr. Reddy’s Laboratories Ltd has received a Form 483 from the US Food and Drug Administration (USFDA) following a detailed inspection of its formulations manufacturing facility (FTO 11) in Srikakulam, Andhra Pradesh.
Key inspection details:
- The inspection was conducted from July 10 to July 18, 2025, covering both Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) protocols.
- The USFDA issued seven observations, highlighting procedural and documentation gaps that require corrective action.
Company response:
- Dr. Reddy’s has confirmed its intent to address all observations within the stipulated timeline.
- The company emphasized its commitment to maintaining global compliance standards and ensuring uninterrupted product supply.
Operational context:
- The Srikakulam facility plays a key role in Dr. Reddy’s global formulations pipeline.
- The inspection outcome may influence future product approvals and regulatory timelines.
Sources: Moneycontrol, The Hindu Business Line, Economic Times Markets, USFDA Inspection Filings
Advertisement
Advertisement